Telbivudine was approved on October 25, 2006, for the treatment of chronic hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Telbivudine

Newsletter